New Schizophrenia Drug Offers Hope But Remains Out of Reach for Many

A novel medication for schizophrenia, Copnevi, has generated significant hope among patients and their families, but its high private cost of approximately 8,000 shekels per pack makes it inaccessible for many. The drug, approved by the FDA in September 2024, operates differently from older antipsychotics by influencing dopamine regulation rather than directly blocking dopamine receptors. This new mechanism may alleviate symptoms with fewer side effects impacting daily functioning, according to Dr. Yoav Dumaney, Director of the Male Psychiatric Department at Ma'ayanei Hayeshua Medical Center, who described it as an important additional option, not a miracle cure.

Copnevi has been submitted for inclusion in Israel's national health basket for the second year and was ranked first by the Psychiatric Association. However, its inclusion is still pending, leaving many families struggling. Yoki, whose 46-year-old son has lived with schizophrenia since his youth, shared that while his current treatment provides stability, it causes severe side effects like drooling, tremors, and weight gain, hindering his social and work integration. "Mental health patients are the weakest and poorest population, and many cannot earn a living and subsist only on minimal disability benefits," she stated. "These families cannot afford the drug if it is not included in the basket."

While Copnevi is available through some supplementary insurance plans, such as Clalit's, and specific programs like the Ministry of Defense's rehabilitation fund and the pharmaceutical company's compassion program, these do not cover all patients. The report, which appeared in "Yedioth Ahronoth," highlights the ongoing battle to make the drug accessible and the challenges faced by those living with the chronic illness.